Charles Ruban (DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT))

Ruban, Charles (DBV Technologies 201709 Chief Commercial Officer before Chief Development Officer)

	Organisation	DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)
	Product	Viaskin® allergy treatment

DBV Technologies S.A.. (9/1/17). "Press Release: DBV Technologies to Attend Upcoming Investor Conferences". Montrouge.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that members of its management team will present and host investor meetings at the following investor conferences in September 2017:

Charles Ruban, Chief Commercial Officer, and Susanna Mesa, SVP, Strategy, will host investor meetings at Citi’s 12th Annual Biotech Conference in Boston, MA, on Thursday, September 7, 2017.

David Schilansky, Chief Operating Officer & Deputy Chief Executive Officer, and Susanna Mesa, SVP, Strategy, will present at the Morgan Stanley 15th Annual Global Healthcare Conference in New York, NY, on Tuesday, September 12, 2017, at 11:45am ET.

A live webcast of the Morgan Stanley 15th Annual Global Healthcare Conference will be available on the Investor Relations section of the Company’s website: http://www.dbvtechnologies.com/en/investor-relations. A replay of the presentation will also be available on DBV’s website within one hour after the event.

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of selfadministered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

DBV Investor Relations Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman@dbv-technologies.com

DBV Media Contact
Roberta Di Giorgio
Head, Corporate Communications
+1 917-612-2861
roberta.digiorgio@dbv-technologies.com

Record changed: 2017-09-06

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]